ACZ885 Phase III Data Show Rapid, Sustained Clinical Remission In Children And Adults Suffering From A Group Of Rare Autoinflammatory Diseases

New Phase III data demonstrate that ACZ885 (canakinumab), a biological drug in development, achieved rapid and long-lasting clinical remission after just one dose in children and adults with a group of rare but potentially life-threatening autoinflammatory diseases called Cryopyrin-Associated Periodic Syndromes (CAPS)1. Due to the long duration of response, patients only needed further treatment every two months1.